Author Correction: Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model

Affiliations

• ¹ B Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
• ² Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.
• ³ Department of Immunology, University of Toronto, Toronto, ON, Canada.
• ⁴ Vector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany.
• ⁵ Malaria Research Group, Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.
• ⁶ Vaccine Formulation Institute, Plan-les-Ouates, Switzerland.
• ⁷ Kymab a Sanofi Company, Babraham Research Campus, Cambridge, UK.
• ⁸ Department of Infectious Diseases, Faculty of Medicine, Imperial College London, London, UK.
• ⁹ Vector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany. levashina@mpiib-berlin.mpg.de.
• ¹⁰ B Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. h.wardemann@dkfz.de.
• ¹¹ Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada. jean-philippe.julien@sickkids.ca.
• ¹² Department of Immunology, University of Toronto, Toronto, ON, Canada. jean-philippe.julien@sickkids.ca.
• ¹³ Department of Biochemistry, University of Toronto, Toronto, ON, Canada. jean-philippe.julien@sickkids.ca.